Skip to main content
    I

    IDEXX Laboratories Inc (IDXX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $700.65
    -3.58 (-0.51%)

    Market Cap: $55.48B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    IDEXX Laboratories Inc (IDXX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    IDEXX Laboratories (IDXX) trades at 47.3x trailing earnings and 11.8x sales. Its P/E of 47.3x is below its 5-year median of 47.6x. Its forward P/E is 41.5x. The median P/E across 11 similar companies is 27.6x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 14.0% higher over the next year. Its free cash flow yield is 2.4%.

    MultipleValue
    P/E (trailing)47.3x
    Forward P/E41.5x
    Price to sales11.8x
    Price to book29.5x
    EV/EBITDA33.6x
    Price to FCF42.4x
    EV/FCF42.9x
    PEG3.3
    FCF yield2.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 11.4% below 53.4x and its P/S is 16.8% above 10.1x.

    MultipleCurrent5-year median10-year median
    P/E47.3x47.6x53.4x
    P/S11.8x10.8x10.1x
    P/B29.5x31.8xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 36.8x in 2024 to 77.4x in 2020.

    Year endPriceP/EP/SP/B
    2025$676.5351.8x12.7x34.0x
    2024$413.4436.8x8.8x21.5x
    2023$555.0555.1x12.6x31.4x
    2022$407.9650.8x10.2x56.2x
    2021$658.4676.5x17.5x82.2x
    2020$499.8777.4x15.8x68.7x
    2019$261.1353.5x9.4x128.3x
    2018$186.0243.6x7.3xN/A
    2017$156.3847.7x7.0xN/A
    2016$117.2747.9x5.9xN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IDXX

    What is IDXX's forward P/E ratio?

    IDEXX Laboratories has a forward P/E ratio of 41.5x.

    Is IDXX stock overvalued?

    GNG's valuation label for IDXX is Undervalued. Its P/E of 47.3x compares with a median of 27.6x across 11 similar companies.

    What is IDXX's price to sales ratio?

    IDEXX Laboratories has a price to sales ratio of 11.8x.

    What is IDEXX Laboratories's average P/E ratio over 5 years?

    IDEXX Laboratories's median P/E over the last 5 years is 47.6x, from 60 month-end values through Oct 2026.

    What is IDXX's PEG ratio?

    IDEXX Laboratories has a PEG ratio of 3.3.